(Q36854624)

16 August 2017

1 reference

title

Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches (English)

1 reference

16 August 2017

0 references

inclusion body myositis

1 reference

Merrilee Needham

1

1 reference

PubMed ID

17582362

16 August 2017

Frank L Mastaglia

series ordinal

2

1 reference

16 August 2017

1 July 2007

1 reference

16 August 2017

1 reference

16 August 2017

6

1 reference

16 August 2017

7

1 reference

16 August 2017

620-631

1 reference

Myxovirus-Like Structures in a Case of Human Chronic Polymyositis

16 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Amyloid filaments in inclusion body myositis. Novel findings provide insight into nature of filaments

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion body myositis: clinical and pathological boundaries.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Epidemiology of inclusion body myositis in the Netherlands: a nationwide study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Prevalence of sporadic inclusion body myositis in Western Australia

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion body myositis mimicking motor neuron disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion-body myositis: a myodegenerative conformational disorder associated with Abeta, protein misfolding, and proteasome inhibition

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Sporadic inclusion body myositis--diagnosis, pathogenesis and therapeutic strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Differences in idiopathic inflammatory myopathy phenotypes and genotypes between Mesoamerican Mestizos and North American Caucasians: ethnogeographic influences in the genetics and clinical expression of myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion body myositis in Connecticut: observations in 35 patients during an 8-year period

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

HLA associations with inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Analysis of HLA class I and II alleles in sporadic inclusion-body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Two major histocompatibility complex haplotypes influence susceptibility to sporadic inclusion body myositis: critical evaluation of an association with HLA-DR3.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Sporadic inclusion body myositis in Japanese is associated with the MHC ancestral haplotype 52.1

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Immunogenetic risk and protective factors for the idiopathic inflammatory myopathies: distinct HLA-A, -B, -Cw, -DRB1 and -DQA1 allelic profiles and motifs define clinicopathologic groups in caucasians

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion body myositis in twins

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Familial inclusion body myositis with histologically confirmed sensorimotor axonal neuropathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

An inflammatory, familial, inclusion body myositis with autoimmune features and a phenotype identical to sporadic inclusion body myositis. Studies in three families

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Familial inclusion body myositis in a mother and son with different ancestral MHC haplotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

New advances in inclusion-body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

"Rimmed vacuole myopathy" sparing the quadriceps. A unique disorder in Iranian Jews

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Distal myopathy with rimmed vacuoles is allelic to hereditary inclusion body myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

GNE mutations in an American family with quadriceps-sparing IBM and lack of mutations in s-IBM

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Sporadic inclusion body myositis not linked to prion protein codon 129 methionine homozygosity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Exons 16 and 17 of the amyloid precursor protein gene in familial inclusion body myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Mitochondrial DNA variants in inclusion body myositis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Apolipoprotein E and inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Apolipoprotein E alleles in sporadic inclusion-body myositis and hereditary inclusion-body myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Apolipoprotein E and alpha-1-antichymotrypsin polymorphisms in sporadic inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Apolipoprotein E type epsilon 4 allele frequency is not increased in patients with sporadic inclusion-body myositis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Apolipoprotein E allele frequencies in sporadic inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

The genetic basis for the association of the 8.1 ancestral haplotype (A1, B8, DR3) with multiple immunopathological diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion body myositis and myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Further observations on forearm flexor weakness in inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Dysphagia in patients with inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion body myositis: atypical clinical presentations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion body myositis presenting with isolated erector spinae paresis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion body myositis. Observations in 40 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion body myositis: peripheral nerve involvement. Combined morphological and electrophysiological studies on peripheral nerves

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Patterns of muscle involvement in inclusion body myositis: clinical and magnetic resonance imaging study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Magnetic resonance imaging of the forearm as a diagnostic aid in patients with sporadic inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Rimmed vacuoles with beta-amyloid and ubiquitinated filamentous deposits in the muscles of patients with long-standing denervation (postpoliomyelitis muscular atrophy): similarities with inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Enhanced detection of congo-red-positive amyloid deposits in muscle fibers of inclusion body myositis and brain of Alzheimer's disease using fluorescence technique

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Immunolocalization of ubiquitin in muscle biopsies of patients with inclusion body myositis and oculopharyngeal muscular dystrophy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Use of anti-neurofilament antibody to identify paired-helical filaments in inclusion-body myositis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Rimmed vacuoles and the added value of SMI-31 staining in diagnosing sporadic inclusion body myositis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion body myositis: morphological clues to correct diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inflammatory disorders of muscle: progress in polymyositis, dermatomyositis and inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Muscle biopsy findings in inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Sporadic inclusion-body myositis and its similarities to Alzheimer disease brain. Recent approaches to diagnosis and pathogenesis, and relation to aging.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Sporadic inclusion body myositis: counts of different types of abnormal fibers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

The molecular and cellular pathology of inflammatory muscle diseases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Major histocompatibility complex class I antigen expression, immunolocalization of interferon subtypes, and T cell-mediated cytotoxicity in myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Expression of immunoreactive major histocompatibility complex products in human skeletal muscles

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Upregulated inducible co-stimulator (ICOS) and ICOS-ligand in inclusion body myositis muscle: significance for CD8+ T cell cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Muscle fibres and cultured muscle cells express the B7.1/2-related inducible co-stimulatory molecule, ICOSL: implications for the pathogenesis of inflammatory myopathies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Clonal restriction of T-cell receptor expression by infiltrating lymphocytes in inclusion body myositis persists over time. Studies in repeated muscle biopsies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

T-cell heterogeneity in muscle lesions of inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion body myositis: clonal expansions of muscle-infiltrating T cells persist over time.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Shared blood and muscle CD8+ T-cell expansions in inclusion body myositis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Cytokines, chemokines, and cell adhesion molecules in inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Local expression of cytokines in idiopathic inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Gene expression profile in the muscles of patients with inflammatory myopathies: effect of therapy with IVIg and biological validation of clinically relevant genes.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Molecular profiles of inflammatory myopathies.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Immune-mediated conditions and antibodies associated with sporadic inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Common variable immunodeficiency and inclusion body myositis: a distinct myopathy mediated by natural killer cells

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion body myositis and paraproteinemia: Incidence and immunopathologic correlations

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Sporadic inclusion body myositis in a patient with human T cell leukemia virus type 1-associated myelopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Direct evidence for a chronic CD8+-T-cell-mediated immune reaction to tax within the muscle of a human T-cell leukemia/lymphoma virus type 1-infected patient with sporadic inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion body myositis in HIV-1 and HTLV-1 infected patients.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion body myositis and chronic immune thrombocytopenia.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion body myositis associated with celiac sprue and idiopathic thrombocytopenic purpura

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Primary Sjögren's syndrome associated with inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion body myositis associated with systemic sarcoidosis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion body myositis associated with systemic lupus erythematosus (SLE)

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Interferon beta-responsive inclusion body myositis in a hepatitis C virus carrier

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Idiopathic inflammatory myopathies: epidemiology, classification, and diagnostic criteria

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Macrophagic myofasciitis associated with inclusion body myositis: a report of three cases

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion body myositis in a patient with a presumed diagnosis of post-polio syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Expression of the costimulatory molecule BB-1, the ligands CTLA-4 and CD28, and their mRNA in inflammatory myopathies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Activation of the endoplasmic reticulum stress response in autoimmune myositis: Potential role in muscle fiber damage and dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Endoplasmic reticulum stress and unfolded protein response in inclusion body myositis muscle.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

The unfolded protein response: a stress signaling pathway critical for health and disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Molecular pathology and pathogenesis of inclusion-body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Immunolocalization of transcription factor NF-kappaB in inclusion-body myositis muscle and at normal human neuromuscular junctions

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Conditional up-regulation of MHC class I in skeletal muscle leads to self-sustaining autoimmune myositis and myositis-specific autoantibodies

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Plasma cells in muscle in inclusion body myositis and polymyositis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion body myositis: explanation for poor response to immunosuppressive therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Beta APP gene transfer into cultured human muscle induces inclusion-body myositis aspects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Amyloid-beta deposition in skeletal muscle of transgenic mice: possible model of inclusion body myopathy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Transgenic mice over-expressing the C-99 fragment of betaPP with an alpha-secretase site mutation develop a myopathy similar to human inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion body myositis-like phenotype induced by transgenic overexpression of beta APP in skeletal muscle

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Genetically augmenting Abeta42 levels in skeletal muscle exacerbates inclusion body myositis-like pathology and motor deficits in transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Proteasome inhibition and aggresome formation in sporadic inclusion-body myositis and in amyloid-beta precursor protein-overexpressing cultured human muscle fibers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Sporadic inclusion-body myositis and hereditary inclusion-body myopathies: diseases of oxidative stress and aging?

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Oxidative stress and predominant Abeta42(43) deposition in myopathies with rimmed vacuoles

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Redox factor-1 in muscle biopsies of patients with inclusion-body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

beta-Amyloid-associated free radical oxidative stress and neurotoxicity: implications for Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

1 reference

7 January 2021

Mutant ubiquitin UBB+1 is accumulated in sporadic inclusion-body myositis muscle fibers.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Molecular misreading: a new type of transcript mutation expressed during aging.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion-body myositis: newest concepts of pathogenesis and relation to aging and Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Proteasomal expression, induction of immunoproteasome subunits, and local MHC class I presentation in myofibrillar myopathy and inclusion body myositis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Involvement of clusterin and the aggresome in abnormal protein deposits in myofibrillar myopathies and inclusion body myositis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

AlphaB-crystallin immunolocalization yields new insights into inclusion body myositis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

AbetaPP-overexpression and proteasome inhibition increase alphaB-crystallin in cultured human muscle: relevance to inclusion-body myositis.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Disease progression in sporadic inclusion body myositis: observations in 78 patients

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

A prospective natural history study of inclusion body myositis: implications for clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

The current status of treatment for inclusion-body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Therapeutic targets in patients with inflammatory myopathies: present approaches and a look to the future

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inflammatory myopathies: clinical, diagnostic and therapeutic aspects

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

The treatment of inclusion body myositis: a retrospective review and a randomized, prospective trial of immunosuppressive therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Mycophenolate (CellCept) treatment of myasthenia gravis, chronic inflammatory polyneuropathy and inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Inclusion body myositis: treatment with intravenous immunoglobulin.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Treatment of inclusion-body myositis with IVIg: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

High-dose immunoglobulin therapy in sporadic inclusion body myositis: a double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Intravenous immunoglobulin for dysphagia of inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Anti-T-lymphocyte globulin treatment in inclusion body myositis: a randomized pilot study.

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Randomized pilot trial of betaINF1a (Avonex) in patients with inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Randomized pilot trial of high-dose betaINF-1a in patients with inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Pilot trial of etanercept in the treatment of inclusion-body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

A pilot randomized trial of oxandrolone in inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Management of Dysphagia in Inclusion Body Myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Injection of botulinum toxin A to the upper esophageal sphincter for oropharyngeal dysphagia in two patients with inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Sporadic inclusion body myositis: pilot study on the effects of a home exercise program on muscle function, histopathology and inflammatory reaction

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Safety and efficacy of strength training in patients with sporadic inclusion body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Effective treatment of severe finger flexion weakness in inclusion body myositis using tendon transfers

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Common structure and toxic function of amyloid oligomers implies a common mechanism of pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Controlling autoimmunity in sporadic inclusion-body myositis

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Three lipoprotein receptors and cholesterol in inclusion-body myositis muscle

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

Progressive myopathy with up-regulation of MHC-I associated with statin therapy

1 reference

https://api.crossref.org/works/10.1016%2FS1474-4422%2807%2970171-0

7 January 2021

10.1016/S1474-4422(07)70171-0

Identifiers

DOI

1 reference

16 August 2017

1 reference

PubMed ID

17582362